85.03
2.75 (3.34%)
| Previous Close | 82.28 |
| Open | 82.28 |
| Volume | 515,693 |
| Avg. Volume (3M) | 452,606 |
| Market Cap | 1,909,618,048 |
| Price / Earnings (TTM) | 53.14 |
| Price / Earnings (Forward) | 9.96 |
| Price / Sales | 2.11 |
| Price / Book | 3.77 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2025 |
| Profit Margin | -3.12% |
| Operating Margin (TTM) | 7.61% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 43.40% |
| Quarterly Earnings Growth (YOY) | -13.90% |
| Total Debt/Equity (MRQ) | 142.03% |
| Current Ratio (MRQ) | 2.66 |
| Operating Cash Flow (TTM) | 80.74 M |
| Levered Free Cash Flow (TTM) | 39.80 M |
| Return on Assets (TTM) | 0.82% |
| Return on Equity (TTM) | -4.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | ANI Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 2.63 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.08% |
| % Held by Institutions | 100.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 124.00 (Guggenheim, 45.83%) | Buy |
| Median | 112.00 (31.72%) | |
| Low | 100.00 (Barclays, 17.61%) | Buy |
| Average | 112.00 (31.72%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 83.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 16 Jan 2026 | 124.00 (45.83%) | Buy | 84.83 |
| 10 Nov 2025 | 115.00 (35.25%) | Buy | 88.93 | |
| Barclays | 09 Dec 2025 | 100.00 (17.61%) | Buy | 81.67 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities |
| 06 Jan 2026 | Announcement | ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Dec 2025 | Announcement | ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise |
| 01 Dec 2025 | Announcement | ANI Pharmaceuticals Announces Board Transition |
| 25 Nov 2025 | Announcement | ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 11 Nov 2025 | Announcement | ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London |
| 07 Nov 2025 | Announcement | ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance |
| 24 Oct 2025 | Announcement | ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |